首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of possible confounding by nutritional status
【24h】

Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of possible confounding by nutritional status

机译:透析结果和实践模式研究(DOPPS)中血液透析患者中​​磷酸盐结合剂的使用和死亡率:通过营养状况评估可能的混淆

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Poor nutritional status and both hyper- and hypophosphatemia are associated with increased mortality in maintenance hemodialysis (HD) patients. We assessed associations of phosphate binder prescription with survival and indicators of nutritional status in maintenance HD patients. Study Design: Prospective cohort study (DOPPS [Dialysis Outcomes and Practice Patterns Study]), 1996-2008. Setting & Participants: 23,898 maintenance HD patients at 923 facilities in 12 countries. Predictors: Patient-level phosphate binder prescription and case-mix-adjusted facility percentage of phosphate binder prescription using an instrumental-variable analysis. Outcome: All-cause mortality. Results: Overall, 88% of patients were prescribed phosphate binders. Distributions of age, comorbid conditions, and other characteristics showed small differences between facilities with higher and lower percentages of phosphate binder prescription. Patient-level phosphate binder prescription was associated strongly at baseline with indicators of better nutrition, ie, higher values for serum creatinine, albumin, normalized protein catabolic rate, and body mass index and absence of cachectic appearance. Overall, patients prescribed phosphate binders had 25% lower mortality (HR, 0.75; 95% CI, 0.68-0.83) when adjusted for serum phosphorus level and other covariates; further adjustment for nutritional indicators attenuated this association (HR, 0.88; 95% CI, 0.80-0.97). However, this inverse association was observed for only patients with serum phosphorus levels <3.5 mg/dL. In the instrumental-variable analysis, case-mix-adjusted facility percentage of phosphate binder prescription (range, 23%-100%) was associated positively with better nutritional status and inversely with mortality (HR for 10% more phosphate binders, 0.93; 95% CI, 0.89-0.96). Further adjustment for nutritional indicators reduced this association to an HR of 0.95 (95% CI, 0.92-0.99). Limitations: Results were based on phosphate binder prescription; phosphate binder and nutritional data were cross-sectional; dietary restriction was not assessed; observational design limits causal inference due to possible residual confounding. Conclusions: Longer survival and better nutritional status were observed for maintenance HD patients prescribed phosphate binders and in facilities with a greater percentage of phosphate binder prescription. Understanding the mechanisms for explaining this effect and ruling out possible residual confounding require additional research.
机译:背景:营养状况不佳以及高磷血症和低磷血症都与维持性血液透析(HD)患者死亡率增加相关。我们评估了维持性HD患者的磷酸盐粘合剂处方与生存率和营养状况指标之间的关联。研究设计:前瞻性队列研究(DOPPS [透析结果和实践模式研究]),1996-2008年。参与者:12个国家/地区的923家机构的23,898名维持高清患者。预测指标:使用工具变量分析的患者水平的磷酸盐粘合剂处方和病例混合调整的磷酸盐粘合剂处方设施百分比。结果:全因死亡率。结果:总体上,有88%的患者使用了磷酸盐粘合剂。年龄,共病条件和其他特征的分布表明,磷酸盐粘合剂处方的百分比较高和较低的设施之间的差异很小。患者水平的磷酸盐结合剂处方在基线时与更好的营养指标密切相关,例如,较高的血清肌酐,白蛋白,标准化的蛋白质分解代谢率,体重指数和缺乏恶病质的外观。总体而言,调整血清磷水平和其他协变量后,开处方磷酸盐结合剂的患者死亡率降低了25%(HR,0.75; 95%CI,0.68-0.83);营养指标的进一步调整减弱了这种联系(HR,0.88; 95%CI,0.80-0.97)。但是,这种反向关联仅在血清磷水平<3.5 mg / dL的患者中观察到。在工具变量分析中,按病例混合调整的磷酸盐粘合剂处方的设备百分比(范围为23%-100%)与更好的营养状况呈正相关,而与死亡率呈负相关(HR比磷酸盐粘合剂高10%,为0.93; 95)。 %CI,0.89-0.96)。营养指标的进一步调整将该关联降低至0.95的HR(95%CI,0.92-0.99)。局限性:结果基于磷酸盐粘合剂处方;磷酸盐粘合剂和营养数据为横断面;没有评估饮食限制;观察性设计限制了因可能的残留混杂而引起的因果推理。结论:维持HD患者使用磷酸盐粘合剂时和在磷酸盐粘合剂处方百分比较高的设施中,观察到更长的生存期和更好的营养状况。要了解解释这种效应的机制并排除可能的残余混杂,还需要进行其他研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号